Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keytruda Filed for Neoadjuvant/Adjuvant Therapy for TNBC in Japan
October 26, 2021
- Rakuten Medical, Karkinos Tie Up in Novel Cancer Care in India
October 25, 2021
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- KM Biologics’ COVID-19 Jab Enters Japan PII/III Study
October 25, 2021
- MSD Seeks Cervical Cancer Nod for Keytruda in Japan
October 25, 2021
- Kaken’s Approval-Pending Eschar Remover Hits Goal in PIII Study
October 22, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
- Taiwan OKs Opdivo-Chemo Combo for Gastric Cancer: Ono
October 21, 2021
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
- Sumitomo Dainippon, BehaVR Seal Deal on VR Digital Therapeutics
October 20, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Japan Joins Global PIII Schizophrenia Program for GlyT1 Inhibitor: BI
October 20, 2021
- Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
- Lenvima/Keytruda Gets European Panel Nod for RCC, Endometrial Carcinoma
October 19, 2021
- JCR’s Hunter Syndrome Drug Earns PRIME Tag in Europe
October 19, 2021
- Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
- Pfizer Japan, Health Tech Startup Join Hands in AI-Powered Support for OAB Patients
October 18, 2021
- Pfizer/Mylan/Viatris to Discontinue 18 Generic Drugs
October 15, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…